Click the image to DOWNLOAD the 2017 Finalist roster ebook
In addition to the live voting taking place at the Awards Ceremony on the 14th September, there is also a weighted public / community vote that will accompany those votes cast on the night.
You can submit your own vote once through the below link. Make it count!
Open to privately owned Life Science companies that are greater than 3 years on from incorporation.
| Bicycle Therapeutics |
| Cell Medica |
| Crescendo Biologics |
| F-Star |
| Immunocore |
| Kymab |
| MISSION Therapeutics |
| PsiOxus Therapeutics |
Open to either private or public life science companies, their Pharma partners and their Advisors.
| Abzena and undisclosed San Diego-based Biopharma - $300m licensing deal |
| Bicycle Therapeutics and AstraZeneca - $1bn peptide collaboration |
| Crescendo Biologics - Takeda $790m cancer collaboration |
| F-Star and Merck – €1bn immuno-oncology collaboration |
| GammaDelta Therapeutics and Takeda - $100m investment / acquisition option |
| PsiOxus Therapeutics and BMS - $936m deal |
| Summit Therapeutics and Sarepta - $584m+ DMD pipeline EU license pact |
| Vectura and Skyepharma merger |
Open to privately owned Life Science companies and their lead investors.
| Artios Pharma - £25m, Series A, SVLS, Touchstone Innovations, Arix Bioscience, Merck Ventures, Abbvie, CRT Pioneer Fund |
| Achilles Therapeutics - £13.2m, Seed Financing, Syncona, CRT Pioneer Fund and the UCL Technology Fund |
| ApcinteX - £14m Series A, Medicxi, Touchstone Innovations |
| Congenica - £10m, Series B, CIC, Amadeus Capital Partners, Parkwalk Advisors |
| NeRRe Therapeutics - £23m, Series B - Advent Life Sciences, Fountain Healthcare Partners, Orbimed, Forbion |
| Oxular - £15.5m, Series A, V-Bio Ventures,Touchstone Innovations, Consort Medical, NeoMed and Hovione Scientia |
| Pulmocide - £24m, Series B, SR-One, SV Life Sciences, Touchstone Innovations, JJVC, F-Prime Capital |
UK PRIVATE FINANCE RAISE OF THE YEAR (>£25M)
Open to privately owned Life Science companies and their lead investors.
Atlas Genetics - £28.3m, Series D, Novartis Venture Funds, Consort Medical plc, Johnson & Johnson Innovation - JJDC, Inc., LSP, BB Biotech Ventures, RMI Partners and Technology Venture Partners, YFM Equity Partners and Wondfo BiotechBicycle Therapeutics - £40m, Series B, Vertex Ventures, Cambridge Innovation Capital, Longwood Fund. Novartis VG, SR-One, SVLS and Atlas Venture
Carrick Therapeutics - £74m, Series A, ARCH Venture Partners and Woodford Investment Management, Cambridge Enterprise, Evotec AG, Google Ventures, Lightstone Venture and Cambridge Innovation Capital
Cell Medica - £60m, Series C, Touchstone Innovations, Invesco Perpetual and Woodford Investment Management
F2G - £46.5m, Series E, Sectoral Asset Management, Novo A/S, Aisling Capital, Advent Life Sciences, Novartis VF, Sunstone, Merifin Capital
Kymab - £78m, Series C,ORI Healthcare Fund
Oxford Nanopore - £100m, Venture Financing, GT Healthcare Healthcare Partners, Woodford Investment Management and IP Group Plc.
Open to newly publicly listed Life Science companies and their Advisors.
| ConvaTec - £1,465m raise, issue price £2.25p (CTEC:LSE) |
| CREO Medical - £21.5m raise, issue price £0.76p (CREO:LSE) |
| Medica Group - £15m raise, issue price £1.35p (MGP:LSE) |
| Oxford Biodynamics - £20m raise, issue price £1.58p (OBD:LSE) |
| SkinBio Therapeutics - £4.5m raise, issue price £0.09p (SBTX:LSE) |
| Verona Pharma - $78m raise, issue price $13.50 (VRNA:US NASDAQ) |
| Widecells - £2m raise, issue price £0.113p (WDC:LSE) |
Open to publicly listed Life Science companies and their Advisors. Raise must be non-IPO.
| Abzena - £25m raised to expand further its service offering, capacity and capabilities |
| C4X Discovery - £7m raised to continue to build its existing pipeline of five preclinical assets |
| Genedrive - £6.5m raised to broaden the portfolio of its Genedrive tests, developed to fight infectious diseases |
| Midatech Pharma - £16m raised to expand and advance its oncology-focused development pipeline |
| Oxford BioMedica - £10m raised to fund progress on its discovery and pre-clinical projects |
| Scancell Holdings - £5m raised to fund clinical work on its pipeline of cancer immune-therapies |
| Verona Pharma - £44.7m raised to fund RPL554 through a phase 2b clinical trial in chronic obstructive pulmonary disease (COPD) patients and additional phase 2 studies in both COPD and cystic fibrosis |
Open to pubicly owned Life Science companies only.
| Abzena |
| Adaptimmune |
| Astrazeneca |
| Clinigen |
| Horizon Discovery |
| Oxford BioMedica |
| Shield Therapeutics |
| Summit Therapeutics |
Open to private or public life science companies and their PR / IR and Strategic Communications Firm.
| Astex Pharmaceuticals and Instinctif |
| Evgen Pharma and Buchanan |
| F2G and Hume Brophy |
| Heptares Therapeutics and Citigate Dewe Rogerson |
| Horizon Discovery and Consilium Strategic Communications |
| Optibiotix and Walbrook PR |
| Verona Pharma and FTI Consulting |
Open to CEOs from both privately and publicly owned Life Science companies.
PRIVATE
| David Chiswell, Kymab |
| John Beadle, PsiOxus Therapeutics |
| John Haurum, F-Star |
| Christian Itin, Autolus |
| Kevin Lee, Bicycle Therapeutics |
| Anker Lundemose, MISSION Therapeutics |
| Peter Pack, Crescendo Biologics |
| Gordon Sanghera, Oxford Nanopore |
PUBLIC
| John Burt, Abzena |
| Shaun Chilton, Clinigen |
| John Dawson, Oxford BioMedica |
| Darrin Disley, Horizon Discovery |
| Clive Dix, C4X Discovery |
| Glyn Edwards, Summit Therapeutics |
| Dame Louise Makin, BTG |
| James Ward-Lilley, Vectura |
